Development

OUR
PIPELINE

We are developing commercial-scale production technologies for diagnostic and therapeutic radioisotopes, increasingly important options for the diagnosis and treatment of serious disease.

Our Programs

Committed to helping patients, NorthStar is advancing a broad portfolio of radiopharmaceuticals for use in therapeutic and diagnostic applications.

Development Scale
Engineering & Chemistry
Proof of Concept
Scale-Up
Data Development
FDA REVIEW
APPROVAL
molybdenum-99 Parent isotope of Tc-99m, the most widely used medical isotope used to diagnose and stage heart disease, cancer, infection, inflammation and other conditions.
COPPER-67 Treatment of a wide variety of adult and childhood cancers including neuroendocrine tumors, neuroblastoma, glioma, lymphoma, etc.
actinium-225 Used in targeted alpha therapy for the treatment of certain forms of cancer, including; leukemia, prostate, brain and neuroendocrine tumors
NMT-009

In-LICENSED PRODUCTS

Development Scale
Engineering & Chemistry
Proof of Concept
Scale-Up
Data Development
FDA REVIEW
APPROVAL
FibroScint Thrombus imaging in patients with mechanical assist device

COLLABORATIONS

Development Scale
Engineering & Chemistry
Proof of Concept
Scale-Up
Data Development
FDA REVIEW
APPROVAL
Monopar Treatment of hyperinflammatory disease
IODINE-123 CAPSULES Diagnosis of thyroid disease
IBA Mo-99 This collaboration is aimed at establishing NorthStar’s accelerator Mo-99 (aMo-99) production capabilities outside of the U.S.

Therapeutic
Radiopharmaceuticals

Therapeutic radiopharmaceuticals are comprised of a therapeutic radioisotope and a targeting molecular carrier that delivers the radioactive drug selectively TO CANCER CELLS, LEAVING HEALTHY CELLS INTACT.

Radioisotopes that decay by beta-particle (negatively charged electrons) or alpha-particle (helium nuclei) emissions are selected for these radiotherapeutics as they can deliver lethal radiation to tumor sites during their radioactive decay. The molecular carriers, such as monoclonal antibodies or peptides, target a specific site on a tumor cell and are designed for high tumor uptake. The radioisotopes are bound to the carrier molecules with a chemical linker to ensure the radionuclide remains attached to the molecule in the bloodstream and is carried to the tumor site to deliver their therapeutic dose. The graphic below demonstrates this process.